These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38485769)

  • 1. Novel cardiovascular therapeutics and the risk of financial toxicity.
    Gunn AH; Pendyal A
    Nat Rev Cardiol; 2024 Jun; 21(6):349-350. PubMed ID: 38485769
    [No Abstract]   [Full Text] [Related]  

  • 2. Orphan Drug Development in Cardiovascular Medicine.
    Khan MS; Vaduganathan M; Butler J
    Circ Cardiovasc Qual Outcomes; 2020 Jul; 13(7):e006509. PubMed ID: 32552063
    [No Abstract]   [Full Text] [Related]  

  • 3. The cost effectiveness of cardiovascular medicines.
    Hay J
    Curr Atheroscler Rep; 2005 Mar; 7(2):79-80. PubMed ID: 15727719
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pharmacoeconomics and cardiovascular disease].
    Anguita Sánchez M
    Rev Clin Esp; 2004 Aug; 204(8):391-2. PubMed ID: 15274760
    [No Abstract]   [Full Text] [Related]  

  • 5. The cost-effectiveness of cardiovascular medicine in Greece: brief notes.
    Vardas PE
    Hellenic J Cardiol; 2012; 53(4):333-4. PubMed ID: 22796825
    [No Abstract]   [Full Text] [Related]  

  • 6. [The elderly cardiovascular patient in general practice. Health care costs--drugs--economic feasibility].
    Schmidt K
    Fortschr Med; 1996 Mar; 114(7):43-4. PubMed ID: 8900969
    [No Abstract]   [Full Text] [Related]  

  • 7. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Terminology I would like to see disappear.
    Detsky AS
    Am Heart J; 1999 May; 137(5):S51-2. PubMed ID: 10220597
    [No Abstract]   [Full Text] [Related]  

  • 8. Current trends in cardiovascular therapy.
    Palmaz JC
    J Cardiovasc Surg (Torino); 2009 Feb; 50(1):3-6. PubMed ID: 19179985
    [No Abstract]   [Full Text] [Related]  

  • 9. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Product labeling and pharmacoeconomic information.
    Morris LA
    Am Heart J; 1999 May; 137(5):S78-80. PubMed ID: 10220603
    [No Abstract]   [Full Text] [Related]  

  • 10. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluating the economic implications of cardiovascular therapeutics.
    Califf RM
    Am Heart J; 1999 May; 137(5):S35-7. PubMed ID: 10220593
    [No Abstract]   [Full Text] [Related]  

  • 11. Merck Serono targets convenient, affordable medicines for patients at risk.
    Cardiovasc J Afr; 2009; 20(1):77. PubMed ID: 19287822
    [No Abstract]   [Full Text] [Related]  

  • 12. Proceedings of a symposium: economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful health economic study for the pharmaceutical industry?
    Gagnon JP
    Am Heart J; 1999 May; 137(5):S62-6. PubMed ID: 10220599
    [No Abstract]   [Full Text] [Related]  

  • 13. Beneficiaries with cardiovascular disease and thePart D coverage gap.
    Polinski JM; Shrank WH; Glynn RJ; Huskamp HA; Roebuck MC; Schneeweiss S
    Circ Cardiovasc Qual Outcomes; 2012 May; 5(3):387-95. PubMed ID: 22511746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving Adherence to Cardiovascular Therapies: An Economic Evaluation of a Randomized Pragmatic Trial.
    Smith DH; O'Keeffe-Rosetti M; Owen-Smith AA; Rand C; Tom J; Vupputuri S; Laws R; Waterbury A; Hankerson-Dyson DD; Yonehara C; Williams A; Schneider J; Dickerson JF; Vollmer WM
    Value Health; 2016; 19(2):176-84. PubMed ID: 27021751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Canadian Cardiovascular Society and reference-based drug pricing.
    Olley PM; McLaughlin PR
    Can J Cardiol; 1998 May; 14(5):669-70. PubMed ID: 9627521
    [No Abstract]   [Full Text] [Related]  

  • 16. The preventive polypill--much promise, insufficient evidence.
    Reddy KS
    N Engl J Med; 2007 Jan; 356(3):212. PubMed ID: 17229947
    [No Abstract]   [Full Text] [Related]  

  • 17. The cost-effectiveness of cardiovascular medicine: victims of our own success?
    Vardas PE
    Hellenic J Cardiol; 2013; 54(2):155-6. PubMed ID: 23557621
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular disease in primary care: concordance and risk reduction.
    Knapton M
    Br J Gen Pract; 2012 Jun; 62(599):284-5. PubMed ID: 22687202
    [No Abstract]   [Full Text] [Related]  

  • 19. The Imminent Demise of Cardiovascular Drug Development.
    Packer M
    JAMA Cardiol; 2017 Dec; 2(12):1293-1294. PubMed ID: 29117286
    [No Abstract]   [Full Text] [Related]  

  • 20. What future does the pharmaceutical industry have in the cardiovascular world?
    Braunwald E
    Eur Heart J; 2013 Apr; 34(13):943-4. PubMed ID: 23546415
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.